

CURRICULUM VITAE

<i>Nome</i>	CLAUDIA PISANU
<i>Nazionalità</i>	Italiana
<i>E-mail</i>	claudia.pisanu@unica.it
<i>Posizione attuale</i>	Professore associato di Farmacologia Indicatori di ricerca (Scopus): H-index: 26, numero di citazioni: 3112 numero di pubblicazioni: 111 Abilitazione ASN SETTORE 05/G1 I fascia valida dal 29/09/2023 al 29/09/2034

ESPERIENZA LAVORATIVA

<i>2024 - Attuale</i>	Professore Associato di Farmacologia, Dipartimento di Scienze Biomediche, Università degli Studi di Cagliari
<i>2024</i>	Visiting Researcher, Keio University, Tokyo (Giappone)
<i>2021 – 2024</i>	Ricercatore a tempo determinato categoria B, Dipartimento di Scienze Biomediche, Università degli Studi di Cagliari
<i>2023</i>	Visiting Researcher, Keio University, Tokyo (Giappone)
<i>2019</i>	Fellow Fondazione Umberto Veronesi
<i>2017 - 2019</i>	Borsista di ricerca, Dipartimento di Scienze Biomediche, Università degli Studi di Cagliari
<i>2018</i>	Special Volunteer, National Institute of Mental Health, National Institute of Health, Bethesda (Maryland, USA)
<i>2015 - 2015</i>	Visiting Researcher, Unit of Functional Pharmacology and Neuroscience, Uppsala University, Uppsala, Sweden

ISTRUZIONE

<i>2019 - 2023</i>	Dottorato di ricerca in Neuroscienze, Università degli Studi di Cagliari, cum laude
<i>2012 - 2017</i>	Specializzazione in Farmacologia Medica, Università degli Studi di Cagliari, 50/50 cum laude
<i>2005 - 2011</i>	Laurea in Medicina e Chirurgia, Università degli Studi di Cagliari, 110/110 cum laude

LINGUE

Inglese (C1 level)

ATTIVITÀ ACCADEMICA

	<i>Presentazioni a congressi</i>
<i>Febbraio 2025 Roma</i>	Speaker di simposio al congresso SOPSI 2025 nel simposio "Personalizzazione della cura per i pazienti con disturbo bipolare" con la presentazione "Predizione della risposta al litio: input dalla multiomica".
<i>Febbraio 2025 Roma</i>	Speaker di simposio al congresso SOPSI 2025 nel simposio "Neuroscienze e psichiatria: personalizzazione e innovazione delle cure"

- attraverso il network di ricerca MNESYS” con la presentazione “Predizione della risposta al litio: non solo genomica?”.
- Gennaio 2025
Milano* Speaker di simposio al congresso SINPF 2025 nel simposio “Prospettive dell’integrazione tra clinica e neurobiologia nel disturbo bipolare” con la presentazione “Genomica del disturbo bipolare: opportunità e nuove prospettive”.
- Settembre 2024
Reykjavik* Speaker di simposio al congresso ISBD 2024 nel simposio “Analysis of Omic Data to Explore the Biological Signatures of Disease Course and Treatment Outcome in Bipolar Disorder” con la presentazione “Multi-Omic Analysis to Identify Peripheral Biomarkers of Lithium Response in Patients with Bipolar Disorder”
- Settembre 2024
Reykjavik* Speaker al congresso ISBD 2024 con la presentazione orale “Genome-Wide Analyses Identify Novel Risk Loci and Shared Genetic Determinants Between Major Depressive Disorder and Parkinson’s Disease”
- Settembre 2024
Milano* Speaker di simposio al congresso ECNP 2024 nel simposio “Implementing precision psychiatry in clinical practice: what are we waiting for?” con la presentazione “The impact of sex and gender differences in precision psychiatry”
- Giugno 2024
Istanbul* Speaker di simposio al congresso WFSBP 2024 nel simposio “Personalized Treatment of Bipolar Disorder” con la presentazione “Multiomics analysis of blood metabolome, gut microbiota and genome-wide methylation to identify biological signatures of response to lithium in Bipolar Disorder”
- Maggio 2024
Cagliari* Speaker su invito al Convegno Congiunto SINPIA-SINPF con la presentazione: “Farmacologia di genere”
- Maggio 2024
Cagliari* Speaker su invito allo Standalone meeting of the ECNP Bipolar Disorders Network con la presentazione “Genome-wide whole blood DNA methylation analysis in patients with bipolar disorder characterized for lithium response”
- Aprile 2024
Cagliari* Speaker al Convegno Monotematico SIF Farmacogenetica con la presentazione “Genome-wide whole blood DNA methylation analysis in patients with bipolar disorder characterized for lithium response”
- Febbraio 2024
Virtual mode* Speaker su invito per il corso e webinar “C4C short course: issues experienced in adolescent clinical trials” con la presentazione “Sex differences in clinical trials”
- Dicembre 2023
Tokyo* Speaker alla Unit of Drug Informatics, Keio University (Tokyo) con la presentazione “Adverse events associated with esketamine: a disproportionality analysis of spontaneous reports through the FDA Adverse Event Reporting System”
- Novembre 2023
Tokyo* Speaker alla Unit of Drug Informatics, Keio University (Tokyo) con la presentazione “Association between migraine prevalence, treatment with proton-pump inhibitors and CYP2C19 phenotypes in the UK Biobank”
- Settembre 2023
Torino* Speaker di simposio alla 20° Conferenza nazionale SINS con la presentazione “Advancing research on psychiatric disorders through multi-omic approaches and pleiotropic analyses applied to genomic data”
- Luglio 2022
Porto* Speaker al congresso “IFCS 2022” con la presentazione “Identification of shared genetic loci between psychiatric disorders and telomere length and evaluation of their Ruolo as potential drug targets”
- Aprile 2021
Virtual mode* Speaker di simposio alla “Society of Biological Psychiatry (SOPB) Conference” con la presentazione “Involvement of microRNAs in Lithium Response in Patients with Bipolar Disorder and Related Phenotypes”
- Ottobre 2020
Virtual mode* Speaker al “World Congress of Psychiatric Genetics (WCPG) 2020” con la presentazione “Investigation of Potential Druggable Genes Shared Between Bipolar Disorder and Risk-Taking Propensity”

- Ottobre 2020
Virtual mode
Speaker su invito al “World Congress of Psychiatric Genetics (WCPG) 2020, Education Day” con la presentazione “Biostatistical Approaches Applied to Lithium Pharmacogenomics”
- Dicembre 2019
Edinburgh
Speaker su invito al congresso “Pharmacology 2019, British Pharmacological Society Conference” con la presentazione “PharmacoloGenius: development of a mobile application to engage in pharmacology”
- Novembre 23 2019
Firenze
Speaker al Congresso nazionale della Società Italiana di Farmacologia (SIF) con la presentazione “Bioinformatics approaches to identify functionally relevant genetic variants: application to the pharmacogenomics of lithium response in bipolar disorder”
- Ottobre 2019
Napoli
Speaker al Congresso della Società Italiana di Psichiatria Biologica (SIPB) con la presentazione “The bidirectional relationship between molecular markers of aging and clinical course and treatment outcome in bipolar disorder and schizophrenia”
- Febbraio 2019
Cagliari
Speaker all’evento “Progetto I Lincei per una nuova didattica nella scuola” con la presentazione “La farmacogenetica come strumento di prevenzione e personalizzazione delle terapie”
- Giugno 2017
Cagliari
Speaker al congresso FederDolore-SICD con la presentazione “Utilizzo degli oppioidi e differenze di genere”
- Giugno e Settembre 2014
Cagliari
Speaker corso ECM “Psicofarmacologia clinica per infermieri, terza edizione”, con la presentazione “Meccanismo d’azione degli antiepilettici e del litio”
- Giugno 2014
Cagliari
Speaker al corso ECM “Cefalea: orientamenti pratici per il medico” con la presentazione “Cefalea da abuso di farmaci”
- Giugno 2014
Torino
Speaker al congresso della Società Italiana di Neuropsicofarmacologia (SINPF) con la presentazione “Target molecolari dei sali di litio: pathway coinvolte nella neuroprotezione”
- Settembre 2012
Cagliari
Speaker corso ECM “Psicofarmacologia clinica per infermieri, seconda edizione”, con la presentazione “Meccanismo d’azione degli antidepressivi e degli antipsicotici”

Consorzi e gruppi di lavoro internazionali

- 2021 - Attuale
Membro del Pharmacogenomics and Transcriptomics Network of the European College of Neuropsychopharmacology (ECNP).
- 2018 - Attuale
Membro dell’International Consortium on Lithium Genetics

Attività editoriale

- 2022 – Attuale
Editorial Board Member per la rivista Brain Research
- 2020 – Attuale
Review editor per le riviste Pharmaceuticals, Frontiers in Pharmacology, Frontiers in Genetics, Frontiers in Neuroscience, Frontiers in Neurology, Frontiers in Psychiatry

Progetti finanziati

- 2025 - 2027
Titolo del progetto: Investigating the interplay between mitochondrial function and inflammation to identify biosignatures of bipolar disorder and of response to long-term lithium treatment. Call: Fondazione di Sardegna 2023. Ruolo: PI

- 2023 - 2025 Titolo del progetto: EXosome MicroRNA ProfiLing to identify biosignatures of mood disorders and treatment Response (EXEMPLAR). Call: Progetti di Rilevante Interesse Nazionale (PRIN 2022). Ruolo: PI
- 2023 - 2025 Titolo del progetto: Biomarkers identification and their interplay investigation in individuals with Parkinson's Disease and new insights on the diagnostic and prognostic value of biomarkers explored by Machine Learning. Call: Start-up Projects finanziata da Università degli Studi di Cagliari. Ruolo: Coordinatore di unità
- 2024 Titolo del progetto: Investigating clinical and genetic determinants underlying the Stevens-Johnson syndrome and other severe adverse drug reactions. Call: Mobilità Giovani Ricercatori MGR2024, finanziato dalla Regione Autonoma della Sardegna. Ruolo: PI
- 2023 Titolo del progetto: Development of clinical models for the prediction of adverse drug reactions: evaluation of gender differences and other demographic or clinical characteristics to identify susceptible subgroups of patients. Call: Mobilità Giovani Ricercatori MGR2023, finanziato dalla Regione Autonoma della Sardegna. Ruolo: PI
- 2022 - 2027 Titolo del progetto: Psych-STRATA - A Stratified Treatment Algorithm in Psychiatry: A program on stratified pharmacogenomics in severe mental illness. Funding Source: Horizon Europe Programme. Call: HORIZON-HLTH-2021-STAYHLTH-01 (Staying Healthy (2021)). Ruolo: Collaboratore.
- 2021 - 2024 Titolo del progetto: The clock is ticking on schizophrenia: a translational study integrating phenotypic, genomic, microbiome and biomolecular data to overcome disability. Ministero della Salute, Bando Ricerca Finalizzata. Call: 2019 Giovani Ricercatori. Ruolo: Coordinatore di unità
- 2021 - 2024 Titolo del progetto: Toward PrecisiOn Medicine for the Prediction of Treatment response in major depressive disorder through stratification of combined clinical and -omics signatures. ERAPerMeD grant, ERA-Net and European Commission Cofund. Call: 2020. Ruolo: Collaboratore
- 2020 - 2023 Titolo del progetto: Multi-omic approach and integration of blood and fecal metabolomic data with gut microbiota to identify biological signatures of response to mood stabilizers in bipolar disorder. Fondazione di Sardegna 2019. Ruolo: Collaboratore
- 2019 - 2021 Titolo del progetto: Pharmacogenetic study on response to antidepressant treatment: characterization of CYP2D6/CYP2C19-based metabolizing properties in patients with major depressive disorder and economic impact of a pharmacogenetic test. Regione Autonoma della Sardegna, L.R. 7/2007. Call: 2017 – DGR 28/21 del 17.05.2015. Ruolo: Collaboratore
- 2018 - 2019 Titolo del progetto: PharmacoloGenius: development of a mobile application to spread pharmacology knowledge. British Pharmacological Society. Ruolo: PI
- 2017 - 2019 Titolo del progetto: Multidisciplinary approach to mental illness: do inflammation and telomere length form a loop? Fondazione di Sardegna and Regione Autonoma della Sardegna, L.R. 7/2007. Call: 2016 – DGR 28/21 del 17.05.2015. Ruolo: Collaboratore
- 2015 - 2016 Titolo del progetto: Development of an Android application for study and research in clinical pharmacology. British Pharmacological Society. Call: Teaching Grant. Ruolo: PI

Premi

- 2023 Vogt prize for excellence in post-graduate studies. Awarded by British Pharmacological Society (BPS)

- 2021 Award SIF-Farindustria per ricerche in campo farmacologico
- 2021 Premio per giovani ricercatori/ricercatrici impegnati/e in progetti riguardanti le differenze di sesso/genere nell'efficacia e nella sicurezza dei farmaci del Centro Studi Nazionale su Salute e Medicina di Genere
- 2021 Award, IUPHAR poster competition, Società Italiana di Farmacologia
- 2021 Award, Best oral communication, Società Italiana di Farmacologia
- 2019 Award, Early Investigator Career Program, International Society of Psychiatric Genetics
- 2019 Fellowship Fondazione Umberto Veronesi
- 2019 Travel grant British Pharmacological Society to attend to Pharmacology 2019 Edinburgh (UK, December 2019)
- 2018 Fellowship GlobusDOC, University of Cagliari
- 2017 Premio per contributo a SIF Farmacogenetica, Società Italiana di Farmacologia
- 2016 Premio per contributo a SIF Farmacogenetica, Società Italiana di Farmacologia
- 2015 EMBL Corporate Partnership Programme Fellowship per partecipare al corso "Statistical Bioinformatics using R and Bioconductor" (Heidelberg)
- 2015 BPS Bain Memorial Bursary Fund per partecipare al congresso Pharmacology 2015 (London)
- 2015 Fellowship, Erasmus PlaceDOC
- 2014 Travel grant per partecipare alla First Insubria International School in Methodology, Ethics and Integrity in biomedical research (Varese)
- 2013 Fellowship per ottenere la certificazione "Evidence based practice", GIMBE
- 2013 Selezionata per partecipare alla prima edizione del Novartis Biotechnology Leadership Camp, Novartis

PUBBLICAZIONI

1. Paribello P, Isayeva U, **Pisanu C**, Squassina A, Manchia M. Pharmacogenomics and response to lithium in bipolar disorder. *Pharmacogenomics*. 2024;25(16-18):689-706. doi: 10.1080/14622416.2025.2470605.
2. Squassina A, Paribello P, Pinna M, Contu M, **Pisanu C**, Congiu D, Severino G, Meloni A, Carta A, Conversano C, Mola F, Del Zompo M, d'Aversa FB, Minelli A, Gennarelli M, Pinna F, Carpiniello B, Manchia M. A naturalistic retrospective evaluation of the utility of pharmacogenetic testing based on CYP2D6 and CYP2C19 profiling in antidepressants treatment in a cohort of patients with major depressive disorder. *Prog Neuropsychopharmacol Biol Psychiatry*. 2025;137:111292. doi: 10.1016/j.pnpbp.2025.111292.
3. O'Connell KS, Koromina M, van der Veen T, ... **Pisanu C**, ... Di Florio A, Ophoff RA, Andreassen OA; Bipolar Disorder Working Group of the Psychiatric Genomics Consortium. Genomics yields biological and phenotypic insights into bipolar disorder. *Nature*. 2025;639(8056):968-975. doi: 10.1038/s41586-024-08468-9.
4. Baune BT, Fromme SE, Aberg M, ... **Pisanu C**, ... Winter-van Rossum I, Young AH, Ziller MJ. A stratified treatment algorithm in psychiatry: a program on stratified pharmacogenomics in severe

- mental illness (Psych-STRATA): concept, objectives and methodologies of a multidisciplinary project funded by Horizon Europe. *Eur Arch Psychiatry Clin Neurosci*. 2024. doi: 10.1007/s00406-024-01944-3.
5. Meloni A, Paribello P, Pinna M, Contu M, Ardaur R, Chillotti C, Congiu D, Gennarelli M, Minelli A, Buson L, Severino G, **Pisanu C**, Manchia M, Squassina A. Mitochondrial DNA copy number is significantly increased in bipolar disorder patients and is correlated with long-term lithium treatment. *Eur Neuropsychopharmacol*. 2025 Feb;91:37-44. doi: 10.1016/j.euroneuro.2024.10.012.
 6. Isayeva U, Paribello P, Ginelli E, **Pisanu C**, Comai S, Carpiniello B, Squassina A, Manchia M. Genomics and pharmacogenomics of cluster headache: implications for personalized management? A systematic review. *Psychiatr Genet*. 2025;35(1):1-11. doi: 10.1097/YPG.0000000000000380. Epub 2024.
 7. Mercuriali G, Lodde L, Paribello P, Sapienza J, Corona A, Ave C, Pacini D, Nocera D, Corrias C, El Kacemi S, D'Incalci M, Frau I, Monzani E, Valtorta F, Congiu D, Meloni A, Scherma M, Fadda P, Dedoni S, Siddi C, Sut S, Dall'Acqua S, Nasini S, Barzon B, Squassina A, Cavallaro R, Manchia M, **Pisanu C**, Bosia M, Comai S. The clock is ticking on schizophrenia: a study protocol for a translational study integrating phenotypic, genomic, microbiome and biomolecular data to overcome disability. *Front Psychiatry*. 2024;15:1451678. doi:10.3389/fpsy.2024.1451678.
 8. Van Assche E, Hohoff C, Su Atil E, Wissing SM, Serretti A, Fabbri C, **Pisanu C**, Squassina A, Minelli A; European College of Neuropsychopharmacology (ECNP) Pharmacogenomics & Transcriptomics Network; Baune BT. Exploring the use of immunomethylomics in the characterization of depressed patients: A proof-of- concept study. *Brain Behav Immun*. 2025;123:597-605. doi:10.1016/j.bbi.2024.09.026.
 9. Zammarchi, G., **Pisanu, C**. Identification of genes shared between sedentary behaviour and inflammation: a bivariate genetic correlation analysis. *Comput Stat* (2024). <https://doi.org/10.1007/s00180-024-01551-9>
 10. **Pisanu C**, Congiu D, Meloni A, Paribello P, Severino G, Ardaur R, Chillotti C, Als TD, Børghlum AD, Del Zompo M, Manchia M, Squassina A. Sex differences in shared genetic determinants between severe mental disorders and metabolic traits. *Psychiatry Res*. 2024;342:116195. doi: 10.1016/j.psychres.2024.116195.
 11. Cocco C, Noli B, Manconi B, Contini C, Manca E, **Pisanu C**, Meloni A, Manchia M, Paribello P, Chillotti C, Ardaur R, Severino G, Squassina A. Lower Plasma Levels of Selective VGF (Non-Acronymic) Peptides in Bipolar Disorder: Comparative Analysis Reveals Distinct Patterns across Mood Disorders and Healthy Controls. *Neuropsychobiology*. 2024 Sep 6:1-10. doi: 10.1159/000540673.
 12. Squassina A, **Pisanu C**, Menesello V, Meloni A, Congiu D, Manchia M, Paribello P, Abate M, Bortolomasi M, Baune BT, Gennarelli M, Minelli A. Leukocyte Telomere Length and Mitochondrial DNA Copy Number in Treatment-Resistant Depression and Response to Electroconvulsive Therapy: A Pilot Longitudinal Study. *J ECT*. 2024 Aug 21. doi: 10.1097/YCT.0000000000001060.
 13. Paribello P, Manchia M, Isayeva U, Upali M, Orrù D, Pinna F, Collu R, Primavera D, Deriu L, Caboni E, Iaselli MN, Sundas D,

- Tusconi M, Scherma M, **Pisanu C**, Meloni A, Zai CC, Congiu D, Squassina A, Fratta W, Fadda P, Carpiniello B. A Secondary Analysis of the Complex Interplay between Psychopathology, Cognitive Functions, Brain Derived Neurotrophic Factor Levels, and Suicide in Psychotic Disorders: Data from a 2-Year Longitudinal Study. *Int J Mol Sci.* 2024 Jul 19;25(14):7922. doi: 10.3390/ijms25147922.
14. Manchia M, Paribello P, Pinna M, Steardo L Jr, Carpiniello B, Pinna F, **Pisanu C**, Squassina A, Hajek T. Lithium and its effects: does dose matter? *Int J Bipolar Disord.* 2024 Jun 24;12(1):23. doi: 10.1186/s40345-024-00345-8.
 15. Manchia M, Paribello P, Pinna M, Steardo L Jr, Carpiniello B, Pinna F, **Pisanu C**, Squassina A, Hajek T. Lithium and its effects: does dose matter? *Int J Bipolar Disord.* 2024 Jun 24;12(1):23. doi: 10.1186/s40345-024-00345-8.
 16. **Pisanu C**, Congiu D, Meloni A, Paribello P, Patrinos GP, Severino G, Ardu R, Chillotti C, Manchia M, Squassina A. Dissecting the genetic overlap between severe mental disorders and markers of cellular aging: Identification of pleiotropic genes and druggable targets. *Neuropsychopharmacology.* 2024;49(6):1033-1041. doi: 10.1038/s41386-024-01822-5.
 17. Herrera-Rivero M, Adli M, Akiyama K ... **Pisanu C** ... Rietschel M, Schulze TG, Baune BT. Exploring the genetics of lithium response in bipolar disorders. *Int J Bipolar Disord.* 2024 Jun 12;12(1):20. doi: 10.1186/s40345-024-00341-y.
 18. Herrera-Rivero M, Gutiérrez-Fragoso K; **International Consortium on Lithium Genetics (ConLi+Gen)**; Kurtz J, Baune BT. Immunogenetics of lithium response and psychiatric phenotypes in patients with bipolar disorder. *Transl Psychiatry.* 2024 Apr 3;14(1):174. doi: 10.1038/s41398-024-02865-4.
 19. Isayeva U, Manchia M, Collu R, Primavera D, Deriu L, Caboni E, Iaselli NM, Sundas D, Tusconi M, Pinna F, Paribello P, Scherma M, **Pisanu C**, Meloni A, Zai CC, Congiu D, Squassina A, Fratta W, Fadda P, Carpiniello B. Symptomatic remission and recovery in major psychosis: Is there a Ruolo for BDNF? A secondary analysis of the LABSP cohort data. *Schizophr Res.* 2024 Apr;266:197-204. doi: 10.1016/j.schres.2024.02.019.
 20. Ou AH, Rosenthal SB, Adli M ... **Pisanu C** ... Young LT, Zandi PP, Kelsoe JR. Lithium response in bipolar disorder is associated with focal adhesion and PI3K-Akt networks: a multi-omics replication study. *Transl Psychiatry.* 2024 Feb 23;14(1):109. doi: 10.1038/s41398-024-02811-4.
 21. Baune BT, Minelli A, Carpiniello B ... **Pisanu C** ... Rybakowski F, Sanz F, Dierssen M. An integrated precision medicine approach in major depressive disorder: a study protocol to create a new algorithm for the prediction of treatment response. *Front Psychiatry.* 2024;14:1279688. doi: 10.3389/fpsy.2023.1279688.
 22. Herrera-Rivero M, Gutiérrez-Fragoso K; **International Consortium on Lithium Genetics (ConLi+Gen)**; Kurtz J, Baune BT. Immunogenetics of lithium response and psychiatric phenotypes in patients with bipolar disorder. *Transl Psychiatry.* 2024 Apr 3;14(1):174. doi: 10.1038/s41398-024-02865-4.
 23. Manchia M, Paribello P, **Pisanu C**, Congiu D, Antoniadis A, Vogazianos P, Tozzi F, Pinna F, Aristodimou A, Caria P, Dettori T, Frau DV, Cocco C, Noli B, Panebianco C, Paziienza V, Carpiniello B, Squassina A. A Pilot Interaction Analysis of Gut

- Microbiota and Peripheral Markers of Aging in Severe Psychiatric Disorders: A Role for Lachnospirillum? *Int J Mol Sci.* 2023 Dec 18;24(24):17618. doi: 10.3390/ijms242417618.
24. Tassan Mazzocco M*, **Pisanu C***, Russo L, Acconcia C, Cambiaghi M, De Girolamo S, Squassina A, Cherchi L, Monzani E, Scebba F, Angeloni D, De Gregorio D, Nasini S, Dall'Acqua S, Sut S, Suprani F, Garzilli M, Guiso B, Pulcinelli V, Iaselli MN, Pinna I, Somaini G, Arru L, Corrias C, Paribello P, Pinna F, Gobbi G, Valtorta F, Carpiniello B, Manchia M, Comai S. Melatonin MT1 receptors as a target for the psychopharmacology of bipolar disorder: A translational study. *Pharmacol Res.* 2023 Dec;198:106993. doi: 10.1016/j.phrs.2023.106993. ***Equal contribution**
 25. Amare AT, Thalamuthu A, Schubert KO ... **Pisanu C** ... Schulze TG, Clark SR, Baune BT. Association of polygenic score and the involvement of cholinergic and glutamatergic pathways with lithium treatment response in patients with bipolar disorder. *Mol Psychiatry.* 2023 Jul 11. doi: 10.1038/s41380-023-02149-1.
 26. **Pisanu C**, Squassina A. RNA Biomarkers in Bipolar Disorder and Response to Mood Stabilizers. *Int J Mol Sci.* 2023 Jun 13;24(12):10067. doi: 10.3390/ijms241210067.
 27. Zai CC, Squassina A, Tiwari AK, **Pisanu C**, Pinna M, Pinna F, Meloni A, Paribello P, Carpiniello B, Tondo L, Frye MA, Biernacka JM, Coombes BJ, Kennedy JL, Manchia M. A genome-wide association study of antidepressant-induced mania. *Prog Neuropsychopharmacol Biol Psychiatry.* 2023 Dec 20;127:110800. doi: 10.1016/j.pnpbp.2023.110800.
 28. Paribello P, Squassina A, **Pisanu C**, Meloni A, Dall'Acqua S, Sut S, Nasini S, Bertazzo A, Congiu D, Garzilli M, Guiso B, Suprani F, Pulcinelli V, Iaselli MN, Pinna I, Somaini G, Arru L, Corrias C, Pinna F, Carpiniello B, Comai S, Manchia M. Probing the Association between Cognition, Suicidal Behavior and Tryptophan Metabolism in a Sample of Individuals Living with Bipolar Disorder: A Secondary Analysis. *Brain Sci.* 2023 Apr 20;13(4):693. doi: 10.3390/brainsci13040693.
 29. Paribello P, Manchia M, Pinna F, Isayeva U, Squassina A, **Pisanu C**, Balderi L, Contu M, Pinna M, Carpiniello B. Pharmacokinetic Markers of Clinical Outcomes in Severe Mental Illness: A Systematic Review. *Int J Mol Sci.* 2023 Mar 1;24(5):4776. doi: 10.3390/ijms24054776.
 30. **Pisanu C**, Squassina A, Paribello P, Dall'Acqua S, Sut S, Nasini S, Bertazzo A, Congiu D, Meloni A, Garzilli M, Guiso B, Suprani F, Pulcinelli V, Iaselli MN, Pinna I, Somaini G, Arru L, Corrias C, Pinna F, Carpiniello B, Comai S, Manchia M. Investigation of Genetic Variants Associated with Tryptophan Metabolite Levels via Serotonin and Kynurenine Pathways in Patients with Bipolar Disorder. *Metabolites.* 2022 Nov 17;12(11):1127. doi: 10.3390/metabo12111127.
 31. Sathyanarayanan A, Mueller TT, Ali Moni M, Schueler K, Baune BT, Lio P, Mehta D; European College of Neuropsychopharmacology (ECNP) Pharmacogenomics & Transcriptomics Network; Baune BT, Dierssen M, Ebert B, Fabbri C, Fusar-Poli P, Gennarelli M, Harmer C, Howes OD, Janzing JGE, Lio P, Maron E, Mehta D, Minelli A, Nonell L, **Pisanu C**, Potier MC, Rybakowski F, Serretti A, Squassina A, Stacey D, van Westrhenen R, Xicota L. Multi-omics data integration methods and their applications in psychiatric disorders. *Eur*

- Neuropsychopharmacol. 2023 Jan 25;69:26-46. doi: 10.1016/j.euroneuro.2023.01.001.
32. Manchia M, Isayeva U, Collu R, Primavera D, Deriu L, Caboni E, Iaselli MN, Sundas D, Tusconi M, Pinna F, Paribello P, Scherma M, **Pisanu C**, Meloni A, Zai CC, Congiu D, Squassina A, Fratta W, Fadda P, Carpiniello B. Converging Evidence Points to BDNF as Biomarker of Depressive Symptoms in Schizophrenia-Spectrum Disorders. *Brain Sci.* 2022 Dec 4;12(12):1666. doi: 10.3390/brainsci12121666.
 33. Coombes BJ, Millischer V, Batzler A ... **Pisanu C** ... Schulze TG, McMahon FJ, Biernacka JM. Association of Attention-Deficit/Hyperactivity Disorder and Depression Polygenic Scores with Lithium Response: A Consortium for Lithium Genetics Study. *Complex Psychiatry.* 2021 Dec;7(3-4):80-89. doi: 10.1159/000519707.
 34. Richie-Halford A, Cieslak M, Ai L, Caffarra S, Covitz S, Franco AR, Karipidis II, Kruper J, Milham M, Avelar-Pereira B, Roy E, Sydnor VJ, Yeatman JD; **Fibr Community Science Consortium**; Satterthwaite TD, Rokem A. An analysis-ready and quality controlled resource for pediatric brain white-matter research. *Sci Data.* 2022 Oct 12;9(1):616. doi: 10.1038/s41597-022-01695-7.
 35. Isayeva U, Manchia M, Collu R, Primavera D, Deriu L, Caboni E, Iaselli N, Sundas D, Tusconi M, Pinna F, Paribello P, Scherma M, **Pisanu C**, Meloni A, Zai CC, Congiu D, Squassina A, Fratta W, Fadda P, Carpiniello B. Exploring the association between brain-derived neurotrophic factor levels and longitudinal psychopathological and cognitive changes in Sardinian psychotic patients. *Eur Psychiatry.* 2022 Oct 25;65(1):e71. doi: 10.1192/j.eurpsy.2022.2333.
 36. Squassina A, Meloni A, Congiu D, Bosganas P, Patrinos GP, Lin R, Turecki G, Severino G, Ardaou R, Chillotti C, **Pisanu C**. Analysis on in vitro effect of lithium on telomere length in lymphoblastoid cell lines from bipolar disorder patients with different clinical response to long-term lithium treatment. *Hum Genomics.* 2022 Oct 17;16(1):45. doi: 10.1186/s40246-022-00418-8.
 37. Carta A, Del Zompo M, Meloni A, Mola F, Paribello P, Pinna F, Pinna M, **Pisanu C**, Manchia M, Squassina A, Carpiniello B, Conversano C. Cost-Utility Analysis of Pharmacogenetic Testing Based on CYP2C19 or CYP2D6 in Major Depressive Disorder: Assessing the Drivers of Different Cost-Effectiveness Levels from an Italian Societal Perspective. *Clin Drug Investig.* 2022 Sep;42(9):733-746. doi: 10.1007/s40261-022-01182-2.
 38. Fellendorf FT, Manchia M, Squassina A, **Pisanu C**, Dall'Acqua S, Sut S, Nasini S, Congiu D, Reininghaus EZ, Garzilli M, Guiso B, Suprani F, Paribello P, Pulcinelli V, Iaselli MN, Pinna I, Somaini G, Arru L, Corrias C, Pinna F, Carpiniello B, Comai S. Is Poor Lithium Response in Individuals with Bipolar Disorder Associated with Increased Degradation of Tryptophan along the Kynurenine Pathway? Results of an Exploratory Study. *J Clin Med.* 2022 Apr29;11(9):2517. doi: 10.3390/jcm11092517.
 39. Bellenguez C, Küçükali F, Jansen IE ... **Pisanu C** ... Ruiz A, Ramirez A, Lambert JC. New insights into the genetic etiology of Alzheimer's disease and related dementias. *Nat Genet.* 2022 Apr;54(4):412-436.
 40. Cearns M, Amare AT, Schubert KO ... **Pisanu C** ... Rietschel M, Clark SR, Baune BT. Using polygenic scores and clinical data for

- bipolar disorder patient stratification and lithium response prediction: machine learning approach. *Br J Psychiatry*. 2022 Feb 28;1-10.
41. **Pisanu C**, Meloni A, Severino G, Squassina A. Genetic and Epigenetic Markers of Lithium Response. *Int. J. Mol. Sci.* 2022, 23(3), 1555.
 42. Kalman JL, Olde Loohuis LM ... **Pisanu C** ... Andlauer TFM, Schulze TG, Ophoff RA. Characterisation of age and polarity at onset in bipolar disorder. *Br J Psychiatry*. 2021 Dec;219(6):659-669.
 43. **Pisanu C**, Severino G, De Toma I, Dierssen M, Fusar-Poli P, Gennarelli M, Lio P, Maffioletti E, Maron E, Mehta D, Minelli A, Potier MC, Serretti A, Stacey D, van Westrhenen R, Xicota L; European College of Neuropsychopharmacology (ECNP) Pharmacogenomics & Transcriptomics Network, Baune BT, Squassina A. Transcriptional biomarkers of response to pharmacological treatments in severe mental disorders: A systematic review. *Eur Neuropsychopharmacol*. 2022 Feb;55:112-157.
 44. Schubert KO, Thalamuthu A, Amare AT ... **Pisanu C** ... Schulze TG, Rietschel M, Baune BT. Combining schizophrenia and depression polygenic risk scores improves the genetic prediction of lithium response in bipolar disorder patients. *Transl Psychiatry*. 2021 Nov 29;11(1):606.
 45. **Pisanu C**, Vitali E, Meloni A, Congiu D, Severino G, Ardaur R, Chillotti C, Trabucchi L, Bortolomasi M, Gennarelli M, Minelli A, Squassina A. Investigating the Ruolo of Leukocyte Telomere Length in Treatment-Resistant Depression and in Response to Electroconvulsive Therapy. *J Pers Med*. 2021 Oct 27;11(11):1100.
 46. Xicota L, De Toma I, Maffioletti E, **Pisanu C**, Squassina A, Baune BT, Potier MC, Stacey D, Dierssen M; European College of Neuropsychopharmacology (ECNP) Pharmacogenomics & Transcriptomics Thematic Workgroup. Recommendations for pharmacotranscriptomic profiling of drug response in CNS disorders. *Eur Neuropsychopharmacol*. 2022 Jan;54:41-53.
 47. Agabio R, **Pisanu C**, Minerba L, Gessa GL, Franconi F. Gender Differences among Sardinians with Alcohol Use Disorder. *J Clin Med*. 2021 Oct 13;10(20):4688.
 48. **Pisanu C**, Welander NZ, Rukh G, Schiöth HB, Mwinyi J. Association between migraine prevalence, treatment with proton-pump inhibitors and CYP2C19 phenotypes in UK Biobank. *Biomed Pharmacother*. 2021 Nov;143:112234.
 49. Le Clerc S, Lombardi L, Baune BT ... **Pisanu C** ... Zagury JF, Leboyer M, Tamouza R. HLA-DRB1 and HLA-DQB1 genetic diversity modulates response to lithium in bipolar affective disorders. *Sci Rep*. 2021 Sep 8;11(1):17823.
 50. Manchia M, Fontana A, Panebianco C, Paribello P, Arzedi C, Cossu E, Garzilli M, Montis MA, Mura A, **Pisanu C**, Congiu D, Copetti M, Pinna F, Pazienza V, Squassina A, Carpiniello B. Involvement of Gut Microbiota in Schizophrenia and Treatment Resistance to Antipsychotics. *Biomedicines*. 2021 Jul 23;9(8):875.
 51. Welander NZ, Olivo G, **Pisanu C**, Rukh G, Schiöth HB, Mwinyi J. Migraine and gastrointestinal disorders in middle and old age: A UK Biobank study. *Brain Behav*. 2021 Aug;11(8):e2291.

52. Pinna M, Manchia M, **Pisanu C**, Pinna F, Paribello P, Carta A, Meloni A, Conversano C, Del Zompo M, Mola F, Squassina A, Carpiniello B. Protocol for a pharmacogenetic study of antidepressants: characterization of drug-metabolizing profiles of cytochromes CYP2D6 and CYP2C19 in a Sardinian population of patients with major depressive disorder. *Psychiatr Genet*. 2021 Oct 1;31(5):186-193.
53. de Rojas I, Moreno-Grau S, Tesi N ... **Pisanu C** ... Lambert JC, van der Lee SJ, Ruiz A. Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. *Nat Commun*. 2021 Jun 7;12(1):3417.
54. **Pisanu C**, Congiu D, Severino G, Ardaù R, Chillotti C, Del Zompo M, Baune BT, Squassina A. Investigation of genetic loci shared between bipolar disorder and risk-taking propensity: potential implications for pharmacological interventions. *Neuropsychopharmacology*. 2021 Aug;46(9):1680-1692.
55. Affatato O, Moulin TC, **Pisanu C**, Babasieva VS, Russo M, Aydinlar EI, Torelli P, Chubarev VN, Tarasov VV, Schiöth HB, Mwinyi J. High efficacy of onabotulinumtoxinA treatment in patients with comorbid migraine and depression: a meta-analysis. *J Transl Med*. 2021 Mar 31;19(1):133.
56. Ghandour F, Squassina A, Karky R, Diab-Assaf M, Fadda P, **Pisanu C**. Presenting Psychiatric and Neurological Symptoms and Signs of Brain Tumors before Diagnosis: A Systematic Review. *Brain Sci*. 2021 Feb 27;11(3):301.
57. Stone W, Nunes A, Akiyama ... **Pisanu C** ... Vieta E, Trappenberg T, Alda M. Prediction of lithium response using genomic data. *Sci Rep*. 2021 Jan 13;11(1):1155.
58. Nunes A, Stone W, Ardaù R ... **Pisanu C** ... Tondo L, Trappenberg T, Alda M. Exemplar scoring identifies genetically separable phenotypes of lithium responsive bipolar disorder. *Transl Psychiatry*. 2021 Jan 11;11(1):36.
59. Squassina A*, Manchia M*, **Pisanu C***, Ardaù R, Arzedi C, Bocchetta A, Caria P, Cocco C, Congiu D, Cossu E, Dettori T, Frau DV, Garzilli M, Manca E, Meloni A, Montis MA, Mura A, Nieddu M, Noli B, Paribello P, Pinna F, Robledo R, Severino G, Sogos V, Del Zompo M, Ferri GL, Chillotti C, Vanni R, Carpiniello B. Telomere attrition and inflammatory load in severe psychiatric disorders and in response to psychotropic medications. *Neuropsychopharmacology*. 2020 Dec;45(13):2229-2238.
* Equal contribution
60. Fontana A, Manchia M, Panebianco C, Paribello P, Arzedi C, Cossu E, Garzilli M, Montis MA, Mura A, **Pisanu C**, Congiu D, Copetti M, Pinna F, Carpiniello B, Squassina A, Paziienza V. Exploring the Ruolo of Gut Microbiota in Major Depressive Disorder and in Treatment Resistance to Antidepressants. *Biomedicines*. 2020 Aug 27;8(9):311.
61. Steardo L Jr, Carbone EA, de Filippis R, **Pisanu C**, Segura-Garcia C, Squassina A, De Fazio P, Steardo L. Application of Support Vector Machine on fMRI Data as Biomarkers in Schizophrenia Diagnosis: A Systematic Review. *Front Psychiatry*. 2020 Jun 23;11:588.
62. Zammarchi G, Del Zompo M, Squassina A, **Pisanu C**. Increasing engagement in pharmacology and pharmacogenetics education using games and online resources: The PharmacoloGenius mobile app. *Drug Dev Res*. 2020 Jul 6.

63. Manchia M, **Pisanu C**, Squassina A, Carpiniello B. Challenges and Future Prospects of Precision Medicine in Psychiatry. *Pharmgenomics Pers Med*. 2020 Apr 23;13:127-140.
64. **Pisanu C**, Congiu D, Manchia M, Caria P, Cocco C, Dettori T, Frau DV, Manca E, Meloni A, Nieddu M, Noli B, Pinna F, Robledo R, Sogos V, Ferri GL, Carpiniello B, Vanni R, Bocchetta A, Severino G, Ardaud R, Chillotti C, Zompo MD, Squassina A. Differences in telomere length between patients with bipolar disorder and controls are influenced by lithium treatment. *Pharmacogenomics*. 2020 Jun;21(8):533-540.
65. Squassina A, Niola P, Lopez JP, Cruceanu C, **Pisanu C**, Congiu D, Severino G, Ardaud R, Chillotti C, Alda M, Turecki G, Del Zompo M. MicroRNA expression profiling of lymphoblasts from bipolar disorder patients who died by suicide, pathway analysis and integration with postmortem brain findings. *Eur Neuropsychopharmacol*. 2020 May;34:39-49.
66. Steardo L Jr, Manchia M, Carpiniello B, **Pisanu C**, Steardo L, Squassina A. Clinical, genetic, and brain imaging predictors of risk for bipolar disorder in high-risk individuals. *Expert Rev Mol Diagn*. 2020 Mar;20(3):327-333.
67. Manchia M, Paribello P, Arzedi C, Bocchetta A, Caria P, Cocco C, Congiu D, Cossu E, Dettori T, Frau DV, Garzilli M, Manca E, Meloni A, Montis MA, Mura A, Nieddu M, Noli B, Pinna F, **Pisanu C**, Robledo R, Severino G, Sogos V, Chillotti C, Carpiniello B, Del Zompo M, Ferri GL, Vanni R, Squassina A. A multidisciplinary approach to mental illness: do inflammation, telomere length and microbiota form a loop? A protocol for a cross-sectional study on the complex relationship between inflammation, telomere length, gut microbiota and psychiatric disorders. *BMJ Open*. 2020 Jan 26;10(1):e032513.
68. Manchia M, Squassina A, **Pisanu C**, Congiu D, Garzilli M, Guiso B, Suprani F, Paribello P, Pulcinelli V, Iaselli MN, Pinna F, Valtorta F, Carpiniello B, Comai S. Investigating the relationship between melatonin levels, melatonin system, microbiota composition and bipolar disorder psychopathology across the different phases of the disease. *Int J Bipolar Disord*. 2019 Dec 9;7(1):27.
69. **Pisanu C**, Merkouri Papadima E, Melis C, Congiu D, Loizedda A, Orrù N, Calza S, Orrù S, Carcassi C, Severino G, Ardaud R, Chillotti C, Del Zompo M, Squassina A. Whole Genome Expression Analyses of miRNAs and mRNAs Suggest the Involvement of miR-320a and miR-155-3p and their Targeted Genes in Lithium Response in Bipolar Disorder. *Int J Mol Sci*. 2019 Nov 30;20(23):6040.
70. **Pisanu C**, Williams MJ, Ciuculete DM, Olivo G, Del Zompo M, Squassina A, Schiöth HB. Evidence that genes involved in hedgehog signaling are associated with both bipolar disorder and high BMI. *Transl Psychiatry*. 2019 Nov 21;9(1):315.
71. **Pisanu C**, Tsermpini EE, Skokou M, Kordou Z, Gourzis P, Assimakopoulos K, Congiu D, Meloni A, Balasopoulos D, Patrinos GP, Squassina A. Leukocyte telomere length is reduced in patients with major depressive disorder. *Drug Dev Res*. 2020 May;81(3):268-273.
72. Nunes A, Ardaud R, Berghöfer A, Bocchetta A, Chillotti C, Deiana V, Garnham J, Grof E, Hajek T, Manchia M, Müller-Oerlinghausen B, Pinna M, **Pisanu C**, O'Donovan C, Severino G, Slaney C, Suwalska A, Zvolosky P, Cervantes P, Del Zompo M, Grof P, Rybakowski J, Tondo L, Trappenberg T, Alda M. Prediction of

- lithium response using clinical data. *Acta Psychiatr Scand.* 2020 Feb;141(2):131-141.
73. **Pisanu C**, Lundin E, Preisig M, Gholam-Rezaee M, Castelao E, Pistis G, Merikangas KR, Glaus J, Squassina A, Del Zompo M, Schiöth HB, Mwinyi J. Major depression subtypes are differentially associated with migraine subtype, prevalence and severity. *Cephalalgia.* 2020 Apr;40(4):347-356.
 74. Kanders SH, **Pisanu C**, Bandstein M, Jonsson J, Castelao E, Pistis G, Gholam-Rezaee M, Eap CB, Preisig M, Schiöth HB, Mwinyi J. A pharmacogenetic risk score for the evaluation of major depression severity under treatment with antidepressants. *Drug Dev Res.* 2020 Feb;81(1):102-113.
 75. **Pisanu C**, Franconi F, Gessa GL, Mameli S, Pisanu GM, Campesi I, Leggio L, Agabio R. Sex differences in the response to opioids for pain relief: A systematic review and meta-analysis. *Pharmacol Res.* 2019 Oct;148:104447.
 76. Scott J, Etain B, Manchia M, Brichant-Petitjean C, Geoffroy PA, Schulze T, Alda M, Bellivier F; **ConLiGen collaborators**. An examination of the quality and performance of the Alda scale for classifying lithium response phenotypes. *Bipolar Disord.* 2020 May;22(3):255-265.
 77. Squassina A, Meloni A, Chillotti C, **Pisanu C**. Zinc finger proteins in psychiatric disorders and response to psychotropic medications. *Psychiatr Genet.* 2019 Oct;29(5):132-141.
 78. Manchia M, **Pisanu C**, Squassina A. Lithium pharmacogenetics. *Psychiatry Res.* 2019 Sep;279:401.
 79. **Pisanu C**, Squassina A. Treatment-Resistant Schizophrenia: Insights From Genetic Studies and Machine Learning Approaches. *Front Pharmacol.* 2019 May 29;10:617.
 80. Melis M, Sollai G, Masala C, **Pisanu C**, Cossu G, Melis M, Sarchioto M, Oppo V, Morelli M, Crnjar R, Hummel T, Tomassini Barbarossa I. Odor Identification Performance in Idiopathic Parkinson's Disease Is Associated With Gender and the Genetic Variability of the Olfactory Binding Protein. *Chem Senses.* 2019 May 29;44(5):311-318.
 81. Squassina A, **Pisanu C**, Vanni R. Mood Disorders, Accelerated Aging, and Inflammation: Is the Link Hidden in Telomeres? *Cells.* 2019 Jan 15;8(1):52.
 82. Skuladottir GV, Oskarsdottir H, **Pisanu C**, Sjödin M, Lindberg J, Mwinyi J, Schiöth HB. Plasma stearyl-CoA desaturase activity indices and bile acid concentrations after a low-fat meal: association with a genetic variant in the FTO gene. *Diabetes Metab Syndr Obes.* 2018 Oct 9;11:611-618.
 83. **Pisanu C**, Congiu D, Costa M, Chillotti C, Ardau R, Severino G, Angius A, Heilbronner U, Hou L, McMahon FJ, Schulze TG, Del Zompo M, Squassina A. Convergent analysis of genome-wide genotyping and transcriptomic data suggests association of zinc finger genes with lithium response in bipolar disorder. *Am J Med Genet B Neuropsychiatr Genet.* 2018 Oct;177(7):658-664.
 84. Ambrosiani L, **Pisanu C**, Deidda A, Chillotti C, Stochino ME, Bocchetta A. Thyroid and renal tumors in patients treated with long-term lithium: case series from a lithium clinic, review of the literature and international pharmacovigilance reports. *Int J Bipolar Disord.* 2018 Aug 6;6(1):17.
 85. **Pisanu C**, Heilbronner U, Squassina A. The Ruolo of Pharmacogenomics in Bipolar Disorder: Moving Towards

- Precision Medicine. *Mol Diagn Ther.* 2018 Aug;22(4):409-420. doi: 10.1007/s40291-018-0335-y. PMID: 29790107.
86. Bocchetta A, Ambrosiani L, Baggiani G, **Pisanu C**, Chillotti C, Ardaù R, Velluzzi F, Piras D, Loviselli A, Pani A. Circulating antithyroid antibodies contribute to the decrease of glomerular filtration rate in lithium-treated patients: a longitudinal study. *Int J Bipolar Disord.* 2018 Mar 1;6(1):3.
 87. **Pisanu C**, Squassina A. We are not Alone in Our Body: Insights into the Involvement of Microbiota in the Etiopathogenesis and Pharmacology of Mental Illness. *Curr Drug Metab.* 2018;19(8):688-694.
 88. **Pisanu C**, Katsila T, Patrinos GP, Squassina A. Recent trends on the Ruolo of epigenomics, metabolomics and noncoding RNAs in rationalizing mood stabilizing treatment. *Pharmacogenomics.* 2018 Jan;19(2):129-143.
 89. **Pisanu C**, Preisig M, Castelao E, Glaus J, Pistis G, Squassina A, Del Zompo M, Merikangas KR, Waeber G, Vollenweider P, Mwinyi J, Schiöth HB. A genetic risk score is differentially associated with migraine with and without aura. *Hum Genet.* 2017 Aug;136(8):999-1008.
 90. **Pisanu C**, Congiu D, Melis C, Severino G, Angius A, Ardaù R, Chillotti C, Del Zompo M, Squassina A. Involvement of core clock genes in lithium response. *World J Biol Psychiatry.* 2018 Dec;19(8):645-646.
 91. Papadima EM, Niola P, Melis C, **Pisanu C**, Congiu D, Cruceanu C, Lopez JP, Turecki G, Ardaù R, Severino G, Chillotti C, Del Zompo M, Squassina A. Evidence towards RNA Binding Motif (RNP1, RRM) Protein 3 (RBM3) as a Potential Biomarker of Lithium Response in Bipolar Disorder Patients. *J Mol Neurosci.* 2017 Aug;62(3-4):304-308.
 92. Deidda A*, **Pisanu C***, Micheletto L, Bocchetta A, Del Zompo M, Stochino ME. Interstitial lung disease induced by fluoxetine: Systematic review of literature and analysis of Vigiaccess, Eudravigilance and a national pharmacovigilance database. *Pharmacol Res.* 2017 Jun;120:294-301. *Equal contribution
 93. Mwinyi J*, **Pisanu C***, Castelao E, Stringhini S, Preisig M, Schiöth HB. Anxiety Disorders are Associated with Low Socioeconomic Status in Women but Not in Men. *Womens Health Issues.* 2017 May-Jun;27(3):302-307. *Equal contribution
 94. Mwinyi J, Boström AE, **Pisanu C**, Murphy SK, Erhart W, Schafmayer C, Hampe J, Moylan C, Schiöth HB. NAFLD is associated with methylation shifts with relevance for the expression of genes involved in lipoprotein particle composition. *Biochim Biophys Acta Mol Cell Biol Lipids.* 2017 Mar;1862(3):314-323.
 95. Agabio R, **Pisanu C**, Gessa GL, Franconi F. Sex Differences in Alcohol Use Disorder. *Curr Med Chem.* 2017;24(24):2661-2670.
 96. **Pisanu C**, Melis C, Squassina A. Lithium Pharmacogenetics: Where Do We Stand? *Drug Dev Res.* 2016 Nov;77(7):368-373.
 97. **Pisanu C**, Papadima EM, Del Zompo M, Squassina A. Understanding the molecular mechanisms underlying mood stabilizer treatments in bipolar disorder: Potential involvement of epigenetics. *Neurosci Lett.* 2018 Mar 16;669:24-31.
 98. **Pisanu C**, Preisig M, Castelao E, Glaus J, Cunningham JL, Del Zompo M, Merikangas KR, Schiöth HB, Mwinyi J. High leptin

- levels are associated with migraine with aura. *Cephalalgia*. 2017 Apr;37(5):435-441.
99. Squassina A*, **Pisanu C***, Congiu D, Caria P, Frau D, Niola P, Melis C, Baggiani G, Lopez JP, Cruceanu C, Turecki G, Severino G, Bocchetta A, Vanni R, Chillotti C, Del Zompo M. Leukocyte telomere length positively correlates with duration of lithium treatment in bipolar disorder patients. *Eur Neuropsychopharmacol*. 2016 Jul;26(7):1241-7. *Equal contribution
100. Agabio R, Campesi I, **Pisanu C**, Gessa GL, Franconi F. Sex differences in substance use disorders: focus on side effects. *Addict Biol*. 2016 Sep;21(5):1030-42.
101. Squassina A, **Pisanu C**, Corbett N, Alda M. Telomere length in bipolar disorder and lithium response. *Eur Neuropsychopharmacol*. 2017 Jun;27(6):560-567.
102. Aas M, Blokland GA, Chawner SJ ... **Pisanu C** ... , Wolfe K, Cormack FK, DeLisi L. Summaries of plenary, symposia, and oral sessions at the XXII World Congress of Psychiatric Genetics, Copenhagen, Denmark, 12-16 October 2014. *Psychiatr Genet*. 2016 Feb;26(1):1-47.
103. **Pisanu C**, Caproni S, Congiu D, Cupini LM, Squassina A, Patrinos GP, Corbelli I, Calabresi P, Del Zompo M, Sarchielli P. HDAC3 Ruolo in medication consumption in medication overuse headache patients: a pilot study. *Hum Genomics*. 2015;9:30.
104. Costa M, Squassina A, Piras IS, **Pisanu C**, Congiu D, Niola P, Angius A, Chillotti C, Ardau R, Severino G, Stochino E, Deidda A, Persico AM, Alda M, Del Zompo M. Preliminary Transcriptome Analysis in Lymphoblasts from Cluster Headache and Bipolar Disorder Patients Implicates Dysregulation of Circadian and Serotonergic Genes. *J Mol Neurosci*. 2015 Jul;56(3):688-95.
105. Deidda A, **Pisanu C**, Garau D, Longu MG, Moretti MD, Sanna ME, Moretti GM, Stochino ME. Squamous-cell carcinoma of the tongue following therapy of rheumatoid arthritis with abatacept. *Clin Case Rep*. 2014 Jun;2(3):66-9.
106. **Pisanu C**, Tsermpini EE, Mavroidi E, Katsila T, Patrinos GP, Squassina A. Assessment of the pharmacogenomics educational environment in Southeast Europe. *Public Health Genomics*. 2014;17(5-6):272-9.
107. **Pisanu C**, Cocco C, Cossu E, Baroni MG, Pigliaru F, Manetti L, Lupi I, Martino E, Mariotti S. Anterior pituitary autoantibodies in patients with type 1 diabetes mellitus: methodological problems and clinical correlations. *J Endocrinol Invest*. 2014 Oct;37(10):973-8.
108. Floris G, Di Stefano F, **Pisanu C**, Chillotti C, Murru MR, Congiu D, Cuccu S, Ruiu E, Borghero G, Cannas A, Marrosu MG, Marrosu F, Del Zompo M, Squassina A. C9ORF72 repeat expansion and bipolar disorder - is there a link? No mutation detected in a Sardinian cohort of patients with bipolar disorder. *Bipolar Disord*. 2014 Sep;16(6):667-8.
109. Squassina A, **Pisanu C**. Personalized medicine in bipolar disorder: how can we overcome the barriers to clinical translation? *Per Med*. 2013 Nov;10(8):765-768.
110. **Pisanu C**, Congiu D, Costa M, Sestu M, Chillotti C, Ardau R, Deiana V, Manchia M, Squassina A, Del Zompo M. No association of endocannabinoid genes with bipolar disorder or

lithium response in a Sardinian sample. *Psychiatry Res.* 2013 Dec 30;210(3):887-90.

111. Severino G, Squassina A, Costa M, **Pisanu C**, Calza S, Alda M, Del Zompo M, Manchia M. Pharmacogenomics of bipolar disorder. *Pharmacogenomics.* 2013 Apr;14(6):655-74.

Capitoli di libri

1. **Pisanu C**, Squassina A. Pharmacogenomics and mood stabilizers: efficacy and adverse drug reactions. In: "Psychiatric Genomics". Tsermpini, Alda, Patrinos eds. Elsevier, 2022. ISBN: 978-0128196021
2. **Pisanu C**, Mameli S, Pisanu G M, Agabio R. The Xs and Y response to opioids in acute and chronic pain. In "A look into the future – The sex and gender pharmacology". Campesi, Colombo, Franconi eds. HPS - Health Publishing & Services Srl, Milan, Italy, 2021. ISBN: 978-88-97719-50-2
3. **Pisanu C**, Squassina A. Pharmacogenomics of bipolar disorder. In: "The Neurobiology of Bipolar Disorder". Quevedo, Carvalho, Vieta eds. Elsevier, 2020 ISBN: 9780128191828
4. **Pisanu C**, Squassina A, Alda M, Severino G. Pharmacogenomics of Bipolar Disorder. In: "Personalized Psychiatry". Baune ed. Elsevier, 2019. ISBN: 9780128131763
5. Squassina A, **Pisanu C**, Alda M. Effect of Lithium on gene expression modulation. In: "The Science and Practice of Lithium Therapy". Malhi, Masson, Bellivier eds. Springer, 2016. ISBN: 3319834002

Autorizzo il trattamento dei dati personali contenuti nel mio curriculum vitae in base all'art. 13 del D. Lgs. 196/2003 e all'art. 13 GDPR 679/16

Cagliari, 14 Aprile 2025